GENERAL COMMENTS
This article describes the proportion of people dying from AAA who might have benefitted from an organized screening program for AAA. It uses a retrospective cross-sectional design, by reviewing all AAA deaths registered in 2010-14 in New Zealand. Although it is a clearly written manuscript and an interesting design, I feel that this approach leads to biased estimates for the benefits of screening. The proportion of persons that would have benefitted form an organized screening program is underestimated because 1) it is assumed that persons diagnosed in the current situation (i.e. without a screening program) due to case finding (opportunistic screening or incidental findings) would not have benefitted of an organized program. First of all, with an organized program, these people might have been diagnosed in an earlier (better treatable) stage. Second, the follow up of these people might have been better in case of an organized (quality controlled) program. Third, the fact that opportunistic screening occurs is not a reason against organized screening. If opportunistic screening shows benefits, this can even be a reason to implement an organized program (which is always better, because of equity and quality control).
2) The authors used a time window of 15 years, which it rather long given the duration of the natural history of AAA. I do agree with the authors that the fact that the incidence of AAA is declining, and persons suffering from AAA have often comorbidities (and shortened life expectancy), it is worthwhile to critically re-evaluate the harms and benefits of AAA screening. Also improvements in surgical techniques needs to be taken into account. But the design used in this manuscript is not suitable to do this re-evaluation, instead a micro-simulation model taking all these issues into account should be used to calculate the harms and benefits of AAA screening. The data showed in this manuscript can be used to feed such a model, or to validate it.
VERSION 1 -AUTHOR RESPONSE
Reviewer(s)' Comments to Author:
Reviewer: 1 Reviewer Name: Janet Powell Institution and Country: Imperial College London, UK Please state any competing interests or state 'None declared': None While we welcome the peer reviewers' comments, we do note that this manuscript suggests a number of considerations that are different from some of the assumptions and modelled input of the recent cost effectiveness modelling paper of which Professor Powell is a co-author.1
Please leave your comments for the authors below 1 It is a major limitation of this manuscript that the prognosis limiting diagnoses eg hip fracture and comorbidities which might mitigate against the decision for AAA repair (eg in-patient in the last 15 years) need patient and public input/discussion not just a public health perspective. A vascular surgical perspective also might be relevant,
We agree with the reviewer that the decision of an AAA repair would indeed require patient's and vascular surgical input. However, we would note that this is not a study examining the decisionmaking process of whether or not an AAA intervention is offered or not. The choice of prognostic limiting diagnoses has a strong empirical basis as referenced and this has been further clarified in the discussion. The disability weights from the Global Burden of Disease study had an extensive range of international academic and public input including face to face interviews. "The choice of prognostic limiting diagnoses were informed by the review of the medical literature,2 or based on disease categories that had empirical data to demonstrate the association of high short term mortality risk,3,4 and/or had been associated with high morbidity burden as defined by the disability weights from the Global Burden of Disease Study.5 " This study is examining the co-morbidities of people who died from AAA to demonstrate that even if all people were offered AAA intervention, many of them would not have the same degree of benefit (in terms of quality and quantity of life gained) as assumed by the published cost effectiveness studies (derived from age matched general population) because competing co-morbidities which we believe have not been adequately factored in the modelling. We hope the paper leads to a helpful discussion about possible over-diagnosis and over-treatment related to the AAA screening program. While the number of AAA repairs would be an important component of an AAA screening evaluation, it should be noted that it is a process measure that is imperfectly aligned with the key outcomes of interest (e.g. all cause mortality, as there will be many repairs provided to people with AAA where the AAA would otherwise have never caused any harm in the person's lifetime).
We have clarified the difference between AAA repairs and deaths are not interchangeable concepts in the discussion: "In the context of inevitably treating people with AAA of whom the AAA would otherwise have never caused harm in their life time, it is important to consider the decision to undertake AAA intervention does not always translate to meaningful benefit to patients overall in terms of quality or quantity of life." . There is no evidence in this manuscript that the patients with a known diagnosis of AAA received any monitoring for this condition. In a screening programme these patients would be followed up. This is a good point by the reviewer. As per the original manuscript submitted, out of 360 people, who had imaging scans prior to AAA death, at least 38% (n=139) had more than 1 scan. We have clarified this point further for the general readers in the results section as follows. "Out of the people (n=360) who had documented abdominal imaging, the first scans were carried out on average 4.2 years prior to death. Within the 15 years prior to death, 139 people had more than one scan, (i.e. had evidence of follow up imaging studies)." This is likely to be a gross under estimate considering as noted in the manuscript that community scans and hospital U/S are largely not captured.
In the discussion, we have moved the comments regarding surveillance and quality improvement of the treatment pathway under the sub heading of "opportunity to improve outcomes of people with AAA without implementing a AAA screening program" "The cohorts with known AAA or who have had prior AAA intervention are more likely to benefit from systematic quality improvement efforts towards surveillance and the management pathway. These can be implemented without a formal screening program. The benefit of this approach is that it can limit the harms and overdiagnoses related a screening program which usually has a primary aim to detect AAA cases.6"
Given the large numbers of co-morbidities demonstrated in this patient cohort however, we believe our main conclusion that there is likely an over-estimate of potential benefit from formal screening still stands.
3 With the declining autopsy rates, deaths from AAA may not be recognised and appropriately coded, particularly in the absence of a known diagnosis of AAA. Therefore the number of deaths from AAA may be an under-estimate. While this is possibility, the actual number is likely to be very small and unlikely to affect the conclusion of the study. We note that the declining AAA mortality rates are seen in many developed countries -the pattern is unlikely to be related to declining autopsies or coroner cases in New Zealand, in the context of improving access to imaging and diagnosis. Furthermore, AAA rupture is usually highly symptomatic, most patients would seek care. In the contemporary setting, imaging studies are widely accessible in an acute or elective setting, and publicly funded in New Zealand, and it is a relatively straightforward diagnosis to make in these circumstances. Autopsies are only offered to cases where deaths are uncertain. We have confirmation from the New Zealand Ministry of Health that they had audited the mortality coding related to AAA, and we have submitted this as supplementary material.
We have added this as a limitation of the study. "It is possible that the number of AAA deaths might be under reported. However, the number of under reporting is likely to be very small if any because of several reasons. Imaging studies are widely accessible in an acute or elective setting, and publicly funded in New Zealand. Rupture of AAA is highly symptomatic, which may prompt the patient to seek care, or provide a co-lateral history that makes misclassification as a cause of death less likely. All sudden, unexpected or unexplained deaths are reported to the coroners in New Zealand.7 Additional investigations and autopsies are undertaken for cases where cause of death was uncertain and/or would be of public interest. Even if there are cases where the AAA rupture are misclassified, the deceased would have been likely to have significant co-morbidities that would have significantly limited any potential benefit accrued from a screening program. It is also possible the people with known AAA who died suddenly from other causes may be misclassified inappropriately as AAA. New Zealand Ministry of Health has reviewed mortality coding related to ruptured AAA and provided reassurance that there is no documented AAA death misclassified by coding."
4 AAA is a cardiovascular disease equivalent and usually those with screen-detected AAA are offered cardiovascular risk reduction therapy, which may improve their long-term survival and explain the effect of AAA screening to reduce all-cause mortality. This important aspect has not been assessed or discussed. This topic was discussed on page 13 paragraph 2 of the submitted manuscript. We have now made this more explicit by making the following additional comment.
Original statement "In the contemporary setting, other potential health and cardiovascular benefits from AAA screening program such as improving CVD management, and support for smoking cessation, are less likely to be realised in countries such as New Zealand where coverage of the eligible population for cardiovascular risk assessment is at 90%.8 Indeed, a weighted meta-regression study of 10 articles demonstrated that out of a group of people with AAA (3.0 to 5.4 cm), there were 8 times more deaths from other cardiovascular causes than from AAA rupture, emphasising the importance of CVD management in people with AAA.9" Additional statement "If one is concerned about CVD risk, then designing interventions to more directly improve systematic CVD risk management in primary care could be suggested without the additional cost and potential harms related to a AAA screening program." 5 For the above reasons, the analysis seems much too simplistic and may result in misleading conclusions. We appreciate this is a complex and controversial topic. Hopefully, we have adequately addressed the reviewers' points raised. However, few countries in the world can provide such population level analyses with coverage over a whole country. Few studies have provided systematic review of a range of co-morbidities that have had an empiric evidence base. We have refined our conclusion in the discussion to "The data in our study suggests many published cost effectiveness modelling papers may overestimate the potential benefit from formal screening. Reasons include falling AAA mortality, high level of co-morbidities, future life expectancy post AAA repair and the impact of incidental detection not being sufficiently taken into account. We agree with the reviewer that with an organised screening program, a person may be treated earlier in an early stage of disease. However, people who were not going to die from AAA would not benefit from AAA intervention (earlier treatment in many cases do not necessarily result in better outcomes, in the context of over diagnosis and over treatment).
We have clarified the difference between AAA repairs and deaths are not interchangeable concepts in the discussion: "In the context of inevitably treating people with AAA of whom the AAA would have otherwise never caused harm in their life time, it is important to consider the decision to undertake AAA intervention does not always translate to meaningful benefit to patients overall in terms of quality or quantity of life." The marginal (additional) health gain from a screening program as compared to incidental diagnosis is beyond the scope of this paper (is a subject of a randomised control trial in the current setting).
What is able to be demonstrated is the large number of co-morbidities that need to be taken into account.
Second, the follow up of these people might have been better in case of an organized (quality controlled) program. We also agree that people within an organised programme with good quality control may get more benefit than people without a formal screening program. However, the quality improvement step of surveillance and management pathway can take place without implementing a formal screening pathway, thereby limiting the harms and over diagnosis and cost of the pathway. As per reply to point 2 of the 1st reviewer We have moved the comment under. "opportunity to improve outcomes of people with AAA without implementing a AAA screening program" "The cohorts with known AAA or had prior AAA intervention are more likely to benefit from systematic quality improvement efforts towards surveillance, and the management pathway which can be implemented. These quality improvement efforts can be implemented formal screening program. The benefit of this approach is to limit the harms and over-diagnoses related to a screening program which usually has a primary aim to detect AAA cases." Third, the fact that opportunistic screening occurs is not a reason against organized screening. If opportunistic screening shows benefits, this can even be a reason to implement an organized program (which is always better, because of equity and quality control). We also agree that high level of opportunistic screening is not a reason against a formal screening program. However, as discussed in the submitted manuscript, from past RCT of AAA screening in areas where there is high background screening, did not demonstrate all cause or AAA mortality benefit from screening. 10,11 Furthermore, a recent matched cohort study suggested that the absolute benefit from AAA screening for men in Sweden was only 7% of the absolute benefit demonstrated by the MASS trial at two avoided AAA deaths from 10,000 invitees. They concluded that the lack of statistical reduction in AAA mortality attributed to a AAA screening program in Sweden, may be associated with the high level of background diagnosis of AAA.12 Therefore, there is evidence to suggest that background screening reduces the effectiveness of a formal screening program. The balance of harms and benefits, and cost effectiveness of opportunistic screening are complex to quantify and this topic is beyond the scope of this paper.
2) The authors used a time window of 15 years, which it rather long given the duration of the natural history of AAA. We sought to capture a longer timeframe to improve the sensitivity of the study. However, the calculation of the multi-morbidity M3 index scores was based on the 5 year time window period only, to ensure comparability with the M3 scores of the general population. This has been further clarified in the methods now in 2 areas. "The M3 index score is a validated multi-morbidity index derived from using log hazard ratios for one year mortality modelled from 61 categories of chronic conditions based on hospital discharge diagnoses in the past 5 years. 3" I do agree with the authors that the fact that the incidence of AAA is declining, and persons suffering from AAA have often co-morbidities (and shortened life expectancy), it is worthwhile to critically reevaluate the harms and benefits of AAA screening. Also improvements in surgical techniques needs to be taken into account. But the design used in this manuscript is not suitable to do this re-evaluation, instead a microsimulation model taking all these issues into account should be used to calculate the harms and benefits of AAA screening. The data showed in this manuscript can be used to feed such a model, or to validate it. We agree with the reviewer that this study can provide an input to future AAA cost-effectiveness modelling. This would assist in addressing a number of limitations in the current cost effectiveness model ling literature. As the reviewer states, this is not a modelling paper or a micro-simulation; rather it is a feeder for those sort of papers. The deaths studied here represent something of a maximum that a screening program could have saved in New Zealand. If screened asymptomatic people were not going to die from AAA then they are not able to be counted as a benefit of the screening program. The conclusion has been amended as follows.
"The data in our study suggests many published cost effectiveness modelling papers may overestimate the potential benefit from formal screening. Reasons include falling AAA mortality, high level of co-morbidities, future life expectancy post AAA repair and the impact of incidental detection not being sufficiently taken into account. The use of real world data from the methods and results are likely to be helpful in calibrating those models."
I still regret that you did not discuss your findings with a representative group of patients and/or the public for their views.
There are a couple of minor issues which require clarification.
1 Page 5, line 36 reads "AAA diagnosis known prior to death even". This diagnosis may have been from screening. Do you mean prior to screening event? 2 Page 14, lines 14-15 reads " Even for people with surgically indicated AAA (5.5 to 6.9cm), the risk of rupture is estimated to be less than 5% per year." This is a misleading sentence on 2 counts. Surgically indicated AAA are 5.5+cm in men and 5,0+ cm in women (see both SVS and ESVS guidelines) and are not limited by a 7 cm threshold. Indeed the risk of rupture of a 7+ cm AAA is 25% per annum and many surgeons will admit patients with AAA of >7 cm for urgent repair. Please rephrase this sentence.
VERSION 2 -AUTHOR RESPONSE
Reviewer: 1
Reviewer Name: Janet Powell Institution and Country: Imperial College London UK Please state any competing interests or state 'None declared': None, despite the authors view to the contrary. My interest lies only in the publication of good quality evidence (without bias).
Please leave your comments for the authors below I think that this manuscript has improved considerably, thank you. I appreciated the information about CVD risk prevention in New Zealand.
Thank you for your comments, which allow the opportunity to provide better clarity on a range of complex issues.
We agree these results would be of interest to a wide range of stakeholders as well as to general public and patient groups. In the current circumstances in our local health system, considering health resources are always finite, such consultation with community input may be better framed as part of the wider prioritisation conversations about a range of funding priorities.
Hence, we have amended to conclusion as follows: The use of real world data from the methods and results are likely to be helpful in calibrating those models "to better inform prioritisation conversations with a variety of stakeholders, including community and patient groups, about a range of competing funding priorities"
1 Page 5, line 36 reads "AAA diagnosis known prior to death event". This diagnosis may have been from screening. Do you mean prior to screening event? In the method section, this has been clarified as AAA diagnosis in the absence of a formal screening program. "AAA diagnosis is known prior to death event in the absence of a formal screening program". This study aims to examine what is the incremental health gain if a formal screening program is implemented compared to current status quo. The section in the discussion on the "Opportunity to improve outcomes of people with AAA without implementing a AAA screening program" provides further detail and clarification of the method.
2 Page 14, lines 14-15 reads "Even for people with surgically indicated AAA (5.5 to 6.9cm), the risk of rupture is estimated to be less than 5% per year." This is a misleading sentence on 2 counts. Surgically indicated AAA are 5.5+cm in men and 5,0+ cm in women (see both SVS and ESVS guidelines) and are not limited by a 7 cm threshold. Indeed the risk of rupture of a 7+ cm AAA is 25% per annum and many surgeons will admit patients with AAA of >7 cm for urgent repair. Please rephrase this sentence.
Thank you for the comment. We have rephrased the sentence to mitigate misinterpretation to "Even for people with 5.5 to 6.9cm AAA which is surgically indicated for AAA repair, the risk of rupture is estimated to be less than 5% per year."
The analyses from the literature was referring to this subgroup of patients, certainly we are not implying this is the only indication for surgical repair. The commentary about optimising management of co-morbidities before elective intervention and conservative treatment for this subgroup we think remains valid and consistent with the literature.1
We agree that people with 7cm+ AAA are of higher risk of rupture, however, the surgical risks are also higher. Decision for surgery should include an informed consent of the potential benefit and risks and patient's preference. We agree that if a decision were to be made to undergo repair, then the repair should be undertaken promptly without undue delay. However, there may still be a role of optimising co-morbidities in some cases, prior to surgical repair as the daily risk of rupture is relatively low, considering majority of these cases do not rupture in a year.
